Publications

• Additional publications can be found at Pubmed: click here.
• Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Predictors of antipsychotic polypharmacy: experience from five western state Medicaid programs (1998-2003). Accepted by Clinical Therapeutics.
• Hartung DM, Ketchum KL, Haxby DG. An evaluation of Oregon's evidence-based practitioner managed prescription drug plan. Health Affairs 2006;25:1423-1432.
• Hamer AM, Hartung DM, Haxby DG, Ketchum KL, Pollack DA. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. J Manag Care Pharm. 2006;12:449-56.
• Haxby D, Drewett R. Selecting antihypertensive therapy. Oregon DUR Board Newsletter. March 2006; 8(2): 1-2.
• Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims based case-contrl study. Pharmacotherapy 2005;25(10): 1329-36.
• Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clinical Therapeutics 2004; 26:1518-32
• Haxby D. Prilosec OTC offers exceptional value for PPI therapy. Oregon DUR Board Newsletter 2004;6(2):1-2
• Hamer A, Haxby D, McFarland B, Ketchum K. Gabapentin use in a managed medicaid population. Journal of Managed Care Pharmacy 2002;8(4):266-71
• Lovell S, Haxby D, Ketchum K. Tagaserod. Is it effective for irritable bowel syndrome? Oregon DUR Board Newsletter 2002;4(8): 1-2
• Syed L, Haxby D. Controlling the rising cost of medications. Oregon DUR Board Newsletter 2001;3(2):4-7.
• Reynolds ER, Boyce RW, Haxby DG, Goldberg BA, Stennett DJ. Intervention assessment in an Indian Health Service Pharmacy. J Am Pharm Assoc 2000;40:41-5
• Haxby D, Jorgensen C, Varley H. Alosetron (Lotronex): A new treatment for irritable bowel syndrome. Oregon DUR Board Newsletter 2000;2(4):1,6-7.
• Vanderveen RP, Abate M, Haxby D. A literature evaluation course delivered via computer assisted instruction, electronic mail, and teleconferences - a case description. Am J Pharm Ed 1999; 63:178-82.
• Haxby D, Fagnan LJ, Furushima H..Recommendations for the treatment of common respiratory tract infections. Oregon DUR Board Newsletter October 1999; 2(2):1-2,5-7
• Slater J, Zechnich AD, Haxby DG. Second generation antihistamines: a comparative review. Drugs 1999; 57(1): 31-47.
• Akers C, Varley H, Haxby D. COX-2 inhibitors- the next generation of NSAIDs: a review of celecoxib (Celebrex). Oregon DUR Board Newsletter 1999; 1(4): 1-3
• Kojiro K, Haxby D. Citolapram: A new SSRI antidepressant. Oregon DUR Board Newsletter 1999; 1(3): 1-3.
• Zechnich AD, Greenlick M, Haxby D, Mullooly J. Elimination of over-the-counter medication coverage in the Oregon Medicaid population: the impact on program costs and drug utilization. Medical Care 1998; 36(8):1283-94.
• Green M, Hamer A, Haxby D, Koder M. New drugs for acute migraine. Oregon DUR Board Newsletter 1998; 1(2):1,6-7.
• Haxby D. Cost-effective use of beta-blockers. Oregon DUR Board Newsletter 1998; 1 (1): 5-6.
• Haxby D. Cost-effective use of NSAIDs. Oregon DUR Board Newsletter 1998; 1(1):6-7.
• Bianco TM, Haxby DG, Vanderveen RP, Boyce R, Lee NL, Muilenburg N. Development of ambulatory clerkships in a managed care setting. Am J Pharm Ed 1996; 60(2):48-53.
• Zechnich AD, Haxby D. Drug interations associated with terfenadine and related non-sedating antihistamines. West J Med 1996; 164:68-9.
• Haxby DG, Baldwin R. The economics of smoking cessation. Am J Health-Syst Pharm 1996; 53:77-9.
• Vanderveen RL, Haxby D, West T, Schuff RA. Student activity analysis of an externship program using multidimensional work sampling. Am J Pharm Ed 1995; 59(3):137-42.
• Haxby DG, Rodriguez GS, Zechnich AD, Schuff RA, Tanigawa JS. Manufacturers= distribution of drug samples to a family medicine clinic. Am J Health - Syst Pharm 1995; 52:496-9.
• Haxby DG. The treatment of nicotine dependence. Am J Health-Syst Pharm 1995;52:265-81.
• Haxby D, Sinclair A, Eiff MP, McQueen MH, Toffler WL. Characteristics and perceptions of nicotine patch users. J Fam Pract 1994; 38(5): 459-64.
• Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994; 160: 321-5.
• Marlow RA, Torrez AJ, Haxby D. The treatment of nonstreptococcal pharyngitis with erythromycin: a preliminary study. Fam Med 1989; 21(6): 425-7.
• Haxby DG, Weart CW, Goodman BW. Family physicians perceptions of the usefulness of drug therapy recommendations from clinical pharmacists. Am J Hosp Pharm 1988; 45: 824-7.

Book Chapters/Booklets

• Bultemeier N, Haxby D. Drug Samples. In: DiPiro Ed. Encyclopedia of Clinical Pharmacy. New York: Marcel Dekker;2002:295-98.
• Haxby D. CareOregon Prescribing Guide. 1998

Non-refereed Publications

• Ketchum K,Haxby D. Oregon State University partners with Medicaid and a managed care organization. Journal of Managed Care Pharmacy 2001; 7(3):185-6
• Haxby D, Toffler WL. Using the nicotine patch to stop smoking. JAMA 1995;273:181-2. (Letter)
• Zechnich AD, Haxby D. The FDA and terfenadine--Drs. Zechnich and Haxby respond. West J Med 1994;161:619-20. (Letter)